Biogen CEO Christopher Viehbacher told analysts the company will slow the pace of M&A for now, pointing to portfolio breadth built through recent acquisitions and deal activity. On an earnings call, he said Biogen is shifting from expanding the substrate of growth toward executing its growth story. The company reaffirmed several late-stage and registrational milestones across neurology and immunology-adjacent programs, including expected systemic lupus erythematosus readouts for litifilimab later this year and additional Phase 3 data in cutaneous lupus. Biogen also pointed to felzartamab for antibody-mediated rejection in kidney transplants and zorevunersen for Dravet syndrome. Biogen is also progressing Alzheimer’s candidate diranersen toward late-stage studies after Phase 2 data suggested cognitive slowdowns across multiple assessments, though those results previously affected the stock amid dose-response confusion. Operationally, the message signals a more disciplined approach to acquisitions, potentially raising focus on data-driven execution and the credibility of upcoming late-stage outcomes.